Antidepressants for depression in adults with HIV infection

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 8, 2014, Pages

  Eshun Wilson, Ingrid ^a   Akena, Dickens H ^b   Siegfried, Nandi ^a,c   Obuku, Ekwaro ^b   Stein, Dan J ^a   Joska, John A ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MAKERERE UNIVERSITY   (Uganda)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; EMPLOYMENT STATUS; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; QUALITY OF LIFE; SUICIDE; SYSTEMATIC REVIEW; THERAPY EFFECT;

EID: 85041962341     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008525.pub2     Document Type: Article

References (63)

1. Akena D, Musisi S, Joska J, Stein D J. The Association between Aids Related Stigma and Major Depressive Disorder among HIV-Positive Individuals in Uganda. PLoS ONE 2012;7(11):e48671. doi:10.1371/journal.pone.0048671.
2. Ammassari A, Antinori A, Aloisi M S, Trotta M P, Murri R, Bartoli L, et al.Depressive Symptoms, Neurocognitive Impairment, and Adherence to Highly Active Antiretroviral Therapy Among HIV-Infected Persons. Psychosomatics 2004;45(5):394-402.
3. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M. Updated research nosology for HIV associated neurocognitive disorders. Neurology 2007;69(18):1789.
4. Beck AT, Ward C, Mendelson M. "Beck Depression Inventory (BDI)". Archives of General Psychiatry 1961;4(6):561-571.
5. Bing E G, Burnam A, Longshore D, Fleishman J A, Sherbourne C D, London A S, et al.Psychiatric Disorders and Drug Use Among Human Immunodeficiency Virus-Infected Adults in the United States. Archives of General Psychiatry 2001;58(8):721-728.
6. Cavalcante G I T. Implications of Efavirenz for Neuropsychiatry: A review. International Journal of Neuroscience 2010;120:739-745.
7. Schneider E, Whitmore S, Glynn M K, Dominguez K, Mitsch A, et al.Revised Surveillance Case Definitions for HIV Infection Among Adults, Adolescents, and Children Aged <18 Months and for HIV Infection and AIDS Among Children Aged 18 Months to <13 Years. Morbidity and Mortality Weekly Report (MMWR) 2008; Vol. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a1.htm.
8. Cespedes M S, Aberg J A. Neuropsychiatric complications of antiretroviral therapy. Drug Saf 2006;29(10):865-74.
9. Ciesla J A, Roberts J E. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001;158(5):725-30.
10. Cohen D E, Walker B D. Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection. Clin Infect Dis 2001;32(12):1756-68.
11. Collins P Y, Holman A R, Freeman M C, Patel V. What is the relevance of mental health to HIV/AIDScare and treatment programs in developing countries? A systematic review. AIDS 2006;20:1571-1582.
12. Cruess D G, Evans D L, Repetto M J, Gettes D, Douglas S D, Petitto J M. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry 2003;54(3):307-16.
13. National Institute of Allergy and Infectious Diseases. Table for Grading the Severity of Adult and Pediatric Adverse Events. Division of AIDS (DAIDS). Regulatory Support Center (RSC) 2004 (clarification 2009); Vol. Version 1.0:Accessed at: http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf.
14. Del Guerra F B, Fonseca J L I, Figueiredo V M, Ziff E B, Castelon Konkiewitz E. Human immunodeficiency virus-associated depression:contributions of immuno-inflammatory, monoaminergic, neurodegenerative, and neurotrophic pathways. Journal of NeuroVirology 2013;19:314-327.
15. DeSilva K E, Le Flore D B, Marston B J, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001;15:1281-1285.
16. Dew M A, Becker J T, Sanchez J, Caldarraro R, Lopez O L, Wess J, Dorst S K, et al.Prevalence and predictors of depressive, anxiety and substance use disorders in HIV-infected and uninfected men: a longitudinal evaluation. Psychological Medicine 1997;27:395-409.
17. DiMatteo M R, Lepper H S, Croghan T W. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160(14):2101-7.
18. Elliott A J, Russo J, Roy-Byrne P P. The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. Gen Hosp Psychiatry 2002;24(1):43-7.
19. Fernandez F, Levy J K. Psychopharmacotherapy of psychiatric syndromes in asymptomatic and symptomatic HIV infection. Psychiatr Med 1991;9(3):377-94.
20. Ferrando S J, Freyberg Z. Treatment of depression in HIV positive individuals: a critical review. Int Rev Psychiatry 2008;20(1):61-71.
21. Foley J, Ettenhofer M, Wright M, Hinkin CH. Emerging Issues in the Neuropsychology of HIV Infection. Current HIV/AIDS Reports 2008;5(4):204-211.
22. Gaynes B N, Pence B W, Atashili J, O'Donnel J, Kats D, Ndumbe P M. Prevalence and predictors of Major Depression in HIV-Infected Patients on Antiretroviral Therapy in Bamenda, a Semi-Urban Center in Cameroon. Plos One 2012;7:e41699.
23. Ghafouri M, Amini S, Khalili K, Sawaya B E. HIV-1 associated dementia: symptoms and causes. Retrovirology 2006;3:28.
24. Gorman J M, Kertzner R, Cooper T, Goetz R R, Lagomasino I, Novacenko H, et al.Glucocorticoid level and neuropsychiatric symptoms in homosexual men with HIV infection. Am J Psychiatry 1991;148(1):41-5.
25. Grant I. Neurocognitive disturbances in HIV. Int Rev Psychiatry 2008;20(1):33-47.
26. Gutiérrez F, García L, Padilla S, Álvarez D, Moreno S, Navarro G, et al.Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs. HIV Medicine 2013;Nov 11:doi: 10.1111/hiv.12104.
27. Guyatt G, Oxman A D, Akl E A, Kunz R, Vist G, Brozek J, et al.GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
28. Hamilton M. Rating depressive patients. Journal of Clinical Psychiatry 1980;41:21-24.
29. Higgins J P T, Green S. Cochrane handbook of systematic reviews. Wiley Blackwell 2009; Vol. Version 5.0.0.
30. Hill L, Lee K C. Pharmacotherapy Considerations in Patients with HIV andPsychiatric Disorders: Focus on Antidepressants andAntipsychotics. Annals of Parmacotherapy 2013;47:75-89.
31. Himelhoch S, Medoff D R. Efficacy of Antidepressant Medication among HIVPositiveIndividuals with Depression: A SystematicReview and Meta-Analysis. AIDS Patient Care and STD's 2005;19(12):813-822.
32. Horberg M A, Silverberg M J, Hurley L B, Towner W J, Klein D B, Bersoff-Matcha S, et al.Effects of Depression and Selective Serotonin Reuptake Inhibitor Use on Adherence to Highly Active Antiretroviral Therapy and on Clinical Outcomes in HIV-Infected Patients. J Acquir Immune Defic Syndr 2008;47:384-90.
33. Huang XL, Cai Q, Rinaldo CR Jr. Natural Killer cell responses in homosexual men with early HIV infection. Journal of Acquired immune Deficiency Syndrome 1990;3:669-676.
34. Ickovics J R, Hamburger M E, Vlahov D, Schoenbaum E E, Shuman P, Boland R J, et al.Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001;285:1466-74.
35. Kinyanda E, Hoskins S, Nakku J, Nawaz S, Patel V. Prevalence and risk factors of major depressive disorder in HIV/AIDS as seen in semi-urbanEntebbe district, Uganda. BioMed Central Psychiatry 2011;11:205.
36. Leserman J, Petitto J M, Perkins D O, Folds J D, Golden R N, Evans D L. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. A 2-year follow-up study. Arch Gen Psychiatry 1997;54(3):279-85.
37. Leserman J, Petitto J M, Golden R N, Gaynes B N, Gu H, Perkins D O, et al.Impact of Stressful Life Events, Depression, Social Support, Coping, and Cortisol on Progression to AIDS. American Journal of Psychiatry 2000;157:1221-1228.
38. Lichtenstein B, Laska M K, Clair J M. Chronic sorrow in the HIV-positive patient: issues of race, gender, and social support. AIDS Patient Care STDS 2002;16(1):27-38.
39. Lima V D, Geller J, Bangsberg D R, Patterson T L, Daniel M, Kerr T, et al.The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. Aids 2007;21(9):1175-83.
40. McArthur J C, Brew B J, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005;4(9):543-55.
41. Morrison M F, Petitto J M, Ten Have T, Gettes D R, Chiappini M S, Weber A L, et al.Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry 2002;159(5):789-96.
42. Murray C J L, Flaxman D, Naghavi M, Lozano R, Michaud C, Ezzati M, et al.Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96.
43. Nakasugga N, Skolasky R L, Musisi S, Allebeck P, Robertson K, Ronald A, et al.Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BioMed Central Psychiatry 2010;10:44.
44. Nakimuli-Mpungu E, Musisi S, Katabira E, Nachega J, Bass J. Prevalence and factors associated with depressive disorders in an HIV positive rural patient population in southern Uganda. Journal of affective disorders 2011;135(1-3):160-7.
45. Nduna M, Jewkes R K, Dunkle K L, Jama Shai N P, Colman I. Associations between depressive symptoms, sexual behaviour and relationship characteristics:a prospective cohort study of young women and men in the Eastern Cape, South Africa. Journal of the International AIDS Society 2012;13:44.
46. Nott K H, Vedhara K. Nature and consequences of stressful life events in homosexual HIV-positive men: a review. AIDS Care 1999;11(2):235-43.
47. Patel R, Kassaye S, Gore-Felton C, Wyshak G, Kadzirange G, Woelk G, et al.Quality of life, psychosocial health, and antiretroviral therapy among HIV-positivewomen in Zimbabwe. AIDS Care 2009;21:1517-1527.
48. Rihs T A, Begley K, Smith D E, Sarangapany J, Callaghan A, Kelly M, et al.Efavirenz and chronic neuropsychiatric symptoms:a cross-sectional case control study. HIV Medicine 2006;7:544.
49. Schuster R, Bornovalova M, Hunt E. The Influence of Depression on the Progression of HIV: Direct and Indirect Effects. Behaviour Modification 36;2:123-145.
50. Shea B J, Grimshaw J M, Wells G A, Boers M, Andersson N, Candyce H, et al.Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007;7:10.
51. Sherbourne C D, Hays R D, Fleishman J A, Vitiello B, Margruder K M, Bing E G, et al.Impact of Psychiatric Conditions on Health-Related Quality of Life in Persons With HIV Infection. American Journal of Psychiatry 2000;157:248-254.
52. Shrier L A, Harris S K, Sternberg M, Beardslee W R. Associations of depression, self-esteem, and substance use with sexual risk among adolescents. Prev Med 2001;33(3):179-89.
53. Siccardi M, Marzolini C, Seden K, Almond L, Kirov A, Khoo S, et al.Prediction of drug-drug Interactions Between VariousAntidepressants and Efavirenz or Boosted Protease InhibitorsUsing a Physiologically Based Pharmacokinetic ModellingApproach. Clinical Pharmacokinetics 2013;52:583-592.
54. Springer S A, Dushaj A, Azar M M. The Impact of DSM-IV Mental Disorders on Adherenceto Combination Antiretroviral Therapy Among Adult PersonsLiving with HIV/AIDS: A Systematic Review. AIDS Behaviour 2012;16:2119-2143.
55. Stein M D, Solomon D A, Herman D S, Anderson B J, Miller I. Depression severity and drug injection HIV risk behaviors. Am J Psychiatry 2003;160(9):1659-62.
56. Tegger M K, Crane H M, Tapia K A, Uldall K K, Holte S E, Kitahata M M. The Effect of Mental Illness, Substance Use, and Treatment for Depression on the Initiation of Highly Active Antiretroviral Therapy among HIV-Infected Individuals. AIDS Patient Care STDS 2008;22(3):233-43.
57. UNAIDS. UNAIDS report on the global AIDS epidemic 2013. http://www.unaids.org/en/resources/campaigns/globalreport2013/factsheet/.
58. Unnikrishnan B, Jagannath V, Ramapuram J T, Achappa B, Madi D. Study of Depression and Its Associated Factors amongWomenLiving with HIV/AIDS in Coastal South India. Intrenational Scholarly Research Network AIDS 2012;2012(ID 684972):1-4.
59. United States Food, Drug Administration. Labeling Information KALETRA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021226s038lbl.pdf.
60. United States Food, Drug Administration. Prescribing information SUSTIVA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020972s043, 021360s031lbl.pdf.
61. Wagner G j, Ghosh-Dastidar B, Slaughter M, Akena D, Nakasujja N, Okello E, Musisi S, et al.The Role of Depression in Work-Related Outcomes of HIV Treatment in Uganda. International Journal of Behavioural Medicine Jan, 2014;e-pub ahead of print:doi:10.1007/s12529-013-9379-x.
62. Watkins CC, Pieper AA, Glenn JT. Safety Considerations in Drug Treatment. Drug Safety 2011;34(8):623-639.
63. World Health Organization. Global Update on HIV treatment 2013: Results, Impact and Opportunities. WHO Report June 2013; Vol. Accessed at: http://apps.who.int/iris/bitstream/10665/85326/1/9789241505734_eng.pdf.